These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20113908)

  • 1. The globalization of clinical trials in pulmonary arterial hypertension.
    Park MH; Rubin LJ
    J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908
    [No Abstract]   [Full Text] [Related]  

  • 2. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
    Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
    Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treprostinil in pulmonary arterial hypertension: Is the glass half full or half empty?
    Provencher S
    Eur Respir J; 2006 Dec; 28(6):1073-5. PubMed ID: 17138674
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy for primary pulmonary hypertension.
    McCormack D
    Can Respir J; 2003 Apr; 10(3):169-70. PubMed ID: 12712230
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostacyclin withdrawal in pulmonary hypertension #264.
    Bartlett C; Landzaat L;
    J Palliat Med; 2013 Feb; 16(2):204-5. PubMed ID: 23336356
    [No Abstract]   [Full Text] [Related]  

  • 6. Transition From Inhaled Treprostinil to Selexipag in Pulmonary Arterial Hypertension.
    El-Kersh K; Smith JS
    Am J Ther; 2017; 24(5):e620-e621. PubMed ID: 27574945
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
    Jacobs W; Boonstra A; Marcus JT; Postmus PE; Vonk-Noordegraaf A
    J Heart Lung Transplant; 2009 Mar; 28(3):280-4. PubMed ID: 19285621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    Poms A; Kingman M
    Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex multidrug therapy in a patient with pulmonary hypertension before and after orthotopic heart transplantation. A case report.
    D'Alto M; Alfano D; Maiello C; Sarubbi B; Santoro G; Argiento P; Galdieri N; Russo MG; Cotrufo M; Calabrò R
    J Cardiovasc Med (Hagerstown); 2007 Nov; 8(11):950-2. PubMed ID: 17906484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of severe pulmonary hypertension associated with COPD treated with epoprostenol].
    Ishikawa S; Yano S; Wakabayashi K; Tokuda Y; Kobayashi K; Ikeda T; Takeyama H
    Nihon Kokyuki Gakkai Zasshi; 2008 Aug; 46(8):660-6. PubMed ID: 18788437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
    Barst RJ; Galie N; Naeije R; Simonneau G; Jeffs R; Arneson C; Rubin LJ
    Eur Respir J; 2006 Dec; 28(6):1195-203. PubMed ID: 16899485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
    Herald N; Laliberte K
    Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
    [No Abstract]   [Full Text] [Related]  

  • 18. Combining treprostinil and sildenafil in the treatment of pulmonary hypertension.
    Chua R; Keogh A
    Intern Med J; 2005 Nov; 35(11):684-5. PubMed ID: 16248867
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.